24 MiMfg Magazine August 2020
@
MFG
Work
What’s Happening
in Michigan
Manufacturing
Magna Invests in
Highland Park;
480 New Jobs
Magna International, an
MMA member since February
2017, announced an expansion
of its seat manufacturing facility
in Highland Park, a project
expected to generate $35.4 million
in private investment and create
480 jobs for Michigan workers.
“This is great news for
Michigan workers, their families,
and our economy as a whole as
we lay a path for economic
recovery and growth here in our
state,” said Governor Gretchen
Whitmer. “This announcement
by Magna further underscores
that Michigan, the state that put
the world on wheels, is the
undisputed location for auto
manufacturers to expand and grow.
It’s time to get Michiganders back
to work and I’m glad to see one of
our state’s longtime employers
investing once again in our state.”
With new full-seat assembly
contracts, Magna’s growth will
require an expansion of its Highland
Park site by approximately 5,000
square feet. The project includes
remodeling the current space,
adding new automated storage
and retrieval shipping systems,
and redesigning all assembly lines
throughout the facility.
“We’ve put a lot of dedication
into managing through the COVID
pandemic, and it’s a good feeling
to have news about growth for
Magna and jobs for people in
Highland Park, Detroit and other
nearby communities,” said Magna
Seating President John Wyskiel.
“We take great pride in being part
of the auto industry, in making
A Magna team member works on a seat at the company’s
soon-to-be-expanded Highland Park manufacturing facility.
great seats for our customers, and
in helping do our part for a safe and
productive economic recovery.”
This announcement builds on
past investments by Magna in
Highland Park and at its mirror
facility in Newaygo.
Learn more at magna.com.
Pfizer Pledges $100M to
Fight Growing Threat of
Antimicrobial Resistance
Pfizer Inc., a 96-year member
of MMA, announced on 7/9/20
that it has pledged $100 million to
the new Antimicrobial Resistance
(AMR) Action Fund to help address
the significant global public health
need for new antibiotics due to the
rise of antibiotic-resistant infections.
The AMR Action Fund is a
groundbreaking collaboration of
more than 20 biopharmaceutical
companies, philanthropies,
development banks, and multilateral
organizations to re-invigorate and
accelerate antibiotic development.
“As the COVID-19 pandemic
has shown, we must invest in the
development of medicines now so
that we are prepared to help
prevent the next public health
crisis,” said Albert Bourla, Pfizer’s
Chairman and Chief Executive.
“We strongly believe the world
cannot tackle the growing threat
of AMR without collaboration —
and that it will take a combination
of prevention measures, responsible
stewardship and innovative
thinking to overcome existing
obstacles. The new AMR Action
Fund gives us the vehicle to do that
by investing in and stimulating a
potentially stronger pipeline for
antimicrobial medicines.”
Each year 700,000 people die
from AMR. By 2050, it is estimated
that AMR could claim as many as
10 million lives per year.
See pfizer.com to learn more.
Got News?
Share your company’s news with
MMA and see it published here,
through our social media channels
or on mimfg.org. Send your
photos, press releases and good
news to MMA’s Brett Gerrish
at [email protected].